Celgene Corp (NASDAQ:CELG)

89.49
Delayed Data
As of 4:00pm ET
 +0.53 / +0.60%
Today’s Change
84.25
Today|||52-Week Range
147.17
-14.25%
Year-to-Date
Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus
11:52am / Zacks.com - Paid Partner Content
Top Research Reports for IBM, McDonald's & Gilead
Apr 19 / Zacks.com - Paid Partner Content
Novartis (NVS) Reports Encouraging Data on MS Candidate
Apr 20 / Zacks.com - Paid Partner Content
Agios' Leukemia Drug Bodes Well for Growth & Strong Pipeline
Apr 18 / Zacks.com - Paid Partner Content
Amgen (AMGN) to Report Q1 Earnings: Is a Beat in the Cards?
Apr 20 / Zacks.com - Paid Partner Content
Alexion (ALXN) to Acquire Wilson Therapeutics for $855M
Apr 12 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close88.95
Today’s open89.24
Day’s range88.71 - 90.03
Volume3,474,523
Average volume (3 months)7,347,724
Market cap$69.6B
Data as of 4:00pm ET, 04/23/2018

Growth & Valuation

Earnings growth (last year)+46.18%
Earnings growth (this year)+13.81%
Earnings growth (next 5 years)+16.45%
Revenue growth (last year)+17.40%
P/E ratio24.6
Price/Sales6.58
Price/Book10.15

Competitors

 Today’s
change
Today’s
% change
BMYBristol-Myers Squibb-0.27-0.53%
GSKGlaxoSmithKline+0.33+0.82%
ABBVAbbVie+0.57+0.62%
SNYSanofi-0.01-0.03%
Data as of 4:02pm ET, 04/23/2018

Financials

Next reporting dateMay 4, 2018
EPS forecast (this quarter)$1.95
Annual revenue (last year)$12.8B
Annual profit (last year)$2.9B
Net profit margin22.93%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President, CEO &
COO
Mark J. Alles
Executive VP, Chief Financial &
Accounting Officer
Peter N. Kellogg
Corporate headquarters
Summit, New Jersey

Forecasts